Top executives from five major PBMs — Derica Rice, executive vice president at CVS; John Prince, CEO of OptumRx; Steve Miller, MD, chief clinical officer at Cigna; Mike Kolar, interim president of Prime Therapeutics; and William Fleming, president of healthcare services at Humana — are set to testify at the hearing about PBMs role in drug pricing.
PBM executives will likely face criticism about the lack of transparency surrounding the practice of drug rebates and for not passing these discounts to patients at the pharmacy counter. In addition, senators will likely grill them about their role in the industry as a whole.
“There’s a lot of secrecy. There’s not a whole lot of understanding of the role they play,” Mr. Grassley told CNBC. “Our goal is to end this secrecy, get to transparency. With transparency comes accountability.”
More articles on pharmacy:
7 drugs projected to become blockbusters by 2023
3 insulin manufacturers to testify at House panel April 10
Cigna-Express Scripts cap out-of-pocket 30-day insulin costs at $25
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
